<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postherpetic neuralgia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postherpetic neuralgia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Postherpetic neuralgia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erik Ortega, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Varicella-zoster virus (VZV) is the causative agent of varicella, or "chickenpox," and herpes zoster, or "shingles." Acute herpes zoster typically presents with a rash that is painful but self-limited. Some patients may continue to experience pain for months to years after the resolution of the rash, a condition known as postherpetic neuralgia (PHN).</p><p>The pathogenesis, epidemiology, clinical features, diagnosis, and treatment of PHN are reviewed here. Other aspects of VZV and the acute therapy of herpes zoster infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Inflammation associated with acute herpes zoster may induce fibrosis and other structural changes in nerves that result in spontaneous activity capable of maintaining pain in the absence of ongoing tissue damage [<a href="#rid1">1-5</a>]. Changes that may contribute to the persistent pain of PHN include spinal or ganglionic hyperexcitability and post-infectious alterations in neuronal gene expression [<a href="#rid6">6,7</a>].</p><p>Acute herpes zoster that precedes PHN is caused by reactivation of the varicella-zoster virus (VZV). Herpes zoster is characterized by hemorrhagic inflammation of the peripheral nerve, dorsal root, and dorsal root ganglion. As cellular immunity wanes with age or immunocompromise, the virus may be transported along peripheral nerves, producing an acute neuritis [<a href="#rid8">8,9</a>]. Extension centrally into the spinal cord and leptomeninges has also been described [<a href="#rid10">10</a>]. Subsequent fibrosis has been reported in the dorsal root ganglion, nerve root, and peripheral nerve following resolution of the acute process [<a href="#rid11">11,12</a>].</p><p>There are three phases of pain associated with herpes zoster [<a href="#rid13">13-15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute herpetic neuralgia refers to pain preceding or accompanying the eruption of rash that may persist for up to 30 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute herpetic neuralgia refers to pain that persists beyond healing of the rash but that resolves within three months of onset.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PHN refers to pain persisting beyond three months from the initial onset of the rash.</p><p></p><p>Autopsy data for cases of well-established PHN are limited. One study reported five cases, three with severe PHN and two with no persistent pain [<a href="#rid16">16</a>]. Findings in patients with persistent pain included dorsal horn atrophy as well as cellular, axonal, and myelin loss with fibrosis in the sensory ganglion. Marked axonal and myelin loss in the nerve and/or sensory root were found in patients both with and without persistent pain.</p><p>A search for responsible neurotransmitters in PHN has been difficult. Substance P is a peptide implicated in the transmission of pain signals, while serotonin and norepinephrine are neurotransmitters thought to play a role in the inhibition of pain signals. However, studies of the affected dorsal horn and dermatomes from patients with PHN have failed to demonstrate differences in cytokine profiles, levels of neurotransmitters, or opiate receptors compared with the unaffected side [<a href="#rid1">1,17,18</a>].</p><p>Some have speculated that ongoing VZV viral replication after an acute infection might be responsible for PHN [<a href="#rid19">19</a>]. However, in a randomized trial of 10 patients with severe PHN, intravenous and oral <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> given for 56 days failed to influence the course of PHN [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H336152504"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>The probability of developing PHN increases with age. The best incidence data in older patients come from the placebo arm of a large randomized trial that evaluated vaccination against the varicella-zoster virus (VZV) [<a href="#rid21">21</a>]. In 334 patients 60 to 69 years of age who developed herpes zoster and were followed for a median of 3.1 years, PHN occurred in 6.9 percent. By contrast, among 308 patients age 70 years or older who developed herpes zoster, PHN occurred in 18.5 percent.</p><p>For adults younger than 60 years of age with herpes zoster, the risk of PHN is estimated to be less than 2 percent [<a href="#rid22">22</a>]. PHN is rare in children.</p><p>The major risk factors for PHN are [<a href="#rid23">23-27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60 years</p><p class="bulletIndent1"><span class="glyph">●</span>Severe or incapacitating pain with acute herpes zoster</p><p class="bulletIndent1"><span class="glyph">●</span>More severe rash with acute herpes zoster</p><p></p><p>Older age is also associated with increasing severity and persistence of PHN symptoms [<a href="#rid28">28</a>]. The risk of PHN may increase with immunosuppression, although the evidence is not entirely consistent [<a href="#rid27">27,29,30</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In most cases, PHN is a continuation of the pain that developed during an acute episode of herpes zoster and never resolved. However, in some cases, PHN pain may develop months to years after resolution of the initial acute event [<a href="#rid31">31</a>]. These episodes occur in the same distribution as the initial rash and are typically precipitated by a specific trigger (eg, a surgical procedure, tooth abscess).</p><p>The pain associated with PHN can be burning, pruritic, sharp, or stabbing and constant or intermittent [<a href="#rid13">13,32</a>]. More than 90 percent of patients with PHN also report allodynia (sensation of pain evoked by normally nonpainful stimuli such as light touch) [<a href="#rid33">33</a>].</p><p>The patient with PHN typically involves a specific nerve and localizes to a dermatome  (<a class="graphic graphic_figure graphicRef106237" href="/d/graphic/106237.html" rel="external">figure 1</a>). Thoracic (typically T4 to T6), cervical, and trigeminal nerves are most commonly affected with PHN [<a href="#rid34">34</a>]. Patients with PHN often report sensory deficits within the affected dermatomes including areas of anesthesia or other specified deficits of thermal, tactile, pinprick, or vibratory sensation [<a href="#rid33">33</a>]. Sensory deficits may extend beyond dermatomal margins, but the contralateral dermatomes are unimpaired. Spontaneous pain may predominate in cutaneous regions with lost or impaired sensation while allodynia may be triggered in other regions with relatively preserved sensation.</p><p>On examination, the areas affected by PHN may show scarring related to the vesicular eruption of the preceding acute herpes zoster infection or by areas of excoriation caused by scratching.</p><p>The pain associated with acute herpes zoster and PHN can be severe and associated with profound psychosocial dysfunction including impaired sleep, decreased appetite, and diminished libido [<a href="#rid32">32,35</a>].</p><p class="headingAnchor" id="H336152363"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2679296440"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of PHN is made when localized neuropathic pain persists beyond three months in the same distribution as a preceding documented episode of acute herpes zoster. (See  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Approach to diagnosis'</a>.)</p><p>In atypical cases of PHN, the characteristic, localized, and persisting pain consistent with PHN supports the diagnosis. Additional factors supporting the diagnosis are [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60 years</p><p class="bulletIndent1"><span class="glyph">●</span>Distribution in trigeminal or brachial plexus dermatomes</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of localized allodynia</p><p class="bulletIndent1"><span class="glyph">●</span>Severe pain or rash with acute herpes zoster episode</p><p></p><p>We obtain neuroimaging, typically magnetic resonance imaging (MRI) with contrast, for patients with atypical clinical presentations including those with dermatomal pain not preceded by an episode of acute herpes zoster and those with neurologic signs or symptoms suggestive of alternative pathologies, such as radiculopathy. Imaging should include the spinal level corresponding to the dermatome of the pain; MRI of the brain is performed for patients with pain in trigeminal or other cranial distributions. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Testing for varicella-zoster virus (VZV) antibodies in the blood or cerebrospinal fluid is available and may be useful in atypical cases to confirm past exposure to the virus; however, positive tests do not specify PHN as the source of pain. (See  <a class="medical medical_review" href="/d/html/8329.html" rel="external">"Diagnosis of varicella-zoster virus infection"</a>.)</p><p class="headingAnchor" id="H3518095601"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The diagnosis is based on the clinical presentation and is straightforward in most cases. However, the diagnosis of PHN can be more challenging when a patient was not diagnosed with (or does not recall) a preceding acute herpes zoster episode [<a href="#rid36">36</a>]. In addition, the identification of a preceding acute herpes zoster episode may be challenging in some patients with PHN whose symptoms began as dermatomally restricted neuropathic pain without rash, a condition called "zoster sine herpete" [<a href="#rid37">37</a>].</p><p>Other causes of focal, persistent neuropathic pain include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trigeminal neuropathy</strong> – Patients with trigeminal neuropathy (ie, anesthesia dolorosa) report pain and reduced sensation in the distribution of the trigeminal nerve. Trigeminal neuropathy may be attributed to PHN, but patients without a history of a preceding rash typical for acute herpes zoster warrant neuroimaging to evaluate for secondary causes such as neoplasm. (See  <a class="medical medical_review" href="/d/html/3355.html" rel="external">"Overview of craniofacial pain", section on 'Painful trigeminal neuropathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other forms of craniofacial pain</strong> – Craniofacial pain syndromes involving nerve distributions other than the trigeminal nerve are described by their distinct characteristics such as headache or cranial neuropathies that may distinguish them from PHN. These syndromes are described separately. (See  <a class="medical medical_review" href="/d/html/3355.html" rel="external">"Overview of craniofacial pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute radiculopathy </strong>– Patients with spinal radiculopathies, often from nerve root compression, may report dermatomal pain but typically also have weakness in the muscles innervated by the affected nerve. Radiculopathies are more common in lumbosacral and cervical regions, unlike PHN, which is more common in thoracic regions. Nerve conduction studies and electromyography as well as spinal imaging may help identify patients with radiculopathies. (See  <a class="medical medical_review" href="/d/html/5271.html" rel="external">"Clinical features and diagnosis of cervical radiculopathy"</a> and  <a class="medical medical_review" href="/d/html/5262.html" rel="external">"Acute lumbosacral radiculopathy: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy</strong> – The onset of pain with diabetic or idiopathic amyotrophy may be acute and focal but typically extends beyond a dermatome. Patients may also report weakness, autonomic symptoms such as orthostatic hypotension or urinary dysfunction, and weight loss. While the pain with PHN is typically lateralized and dermatomally restricted, diabetic and idiopathic amyotrophy frequently progresses to become more widespread and involve the contralateral side. (See  <a class="medical medical_review" href="/d/html/5268.html" rel="external">"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent acute herpes zoster</strong> – Neuropathic pain may be prolonged in patients who develop a recurrent episode of acute herpes zoster. The recurrent acute attack may be identified by a recurring rash along with the neuritis. Recurrent acute herpes zoster is likelier to occur in immunocompromised patients. (See  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Recurrent herpes zoster'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Multiple medications have shown benefit in reducing PHN symptoms. However, PHN can be difficult to treat, and some patients require multimodal therapy to manage symptoms. The choice among treatments for PHN should be individualized according to the severity and location of pain, comorbid conditions, medication side effect profile, treatment cost and availability, and patient values and preferences  (<a class="graphic graphic_algorithm graphicRef133184" href="/d/graphic/133184.html" rel="external">algorithm 1</a>). Because the pain of PHN may be chronic, long-term therapy is often required [<a href="#rid38">38</a>]. However, the long-term benefits of most therapies are uncertain, and side effects are common [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H2771660676"><span class="h2">Initial therapies</span><span class="headingEndMark"> — </span>Both gabapentinoids (ie, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>) and tricyclic antidepressants (TCAs) have been found to be effective and generally well tolerated for PHN in clinical trials and meta-analyses [<a href="#rid40">40-44</a>]. Gabapentinoids may have a lower risk of discontinuation due to adverse effects than TCAs, but these agents have not been compared directly for PHN. We use patient variables including medication side effect profile, comorbid conditions, and symptom severity to help select initial therapy. As examples, gabapentin or pregabalin may be preferred for patients to help co-treat a seizure disorder or to avoid the risk of cognitive impairment associated with TCAs. <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> or other TCAs may be preferred for patients to help co-treat depression.</p><p class="headingAnchor" id="H799182267"><span class="h3">Gabapentinoids for most patients with moderate or severe pain</span><span class="headingEndMark"> — </span>For most patients with moderate to severe pain, we suggest a gabapentinoid (<a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>) as initial therapy [<a href="#rid45">45</a>]. Gabapentin and pregabalin are structural analogs of gamma-aminobutyric acid (GABA) and have been approved by the US Food and Drug Administration (FDA) for PHN. Both are generally well tolerated and neither alters the pharmacokinetics of other medications because neither binds to plasma proteins [<a href="#rid46">46,47</a>]. We typically start with gabapentin because of lower cost and more favorable tolerability [<a href="#rid43">43</a>]. However, pregabalin is also a reasonable initial choice for PHN based on efficacy because there are no direct comparisons with gabapentin.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gabapentin</strong> − <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> is typically started at a low dose to minimize the risk of discontinuation from adverse effects. The daily dose is titrated to effect, for most patients typically from 1800 up to 3600 mg. Our suggested initial titration of the immediate release formulation of gabapentin for PHN is:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>300 mg on day 1</p><p class="bulletIndent2"><span class="glyph">•</span>300 mg twice daily on day 2</p><p class="bulletIndent2"><span class="glyph">•</span>300 mg three times daily on day 3 </p><p class="bulletIndent2"><span class="glyph">•</span>Thereafter, increase as needed by 300 mg every three days up to 600 mg three times daily</p><p></p><p class="bulletIndent1">Lower doses may be used or the titration may be slowed for patients who report relief or adverse effects at intermediate doses during the initial titration.</p><p></p><p class="bulletIndent1">For patients who report minimal or no relief after one month at a total daily dose of 1800 mg, we switch to a TCA. (See <a class="local">'Tricyclic antidepressants if gabapentinoids ineffective or not tolerated'</a> below.)</p><p></p><p class="bulletIndent1">For patients who report partial but inadequate pain relief at a total daily dose of 1800 mg, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> may be further increased as needed and tolerated by up to 600 mg each week to a maximum of 3600 mg given in three divided doses.</p><p></p><p class="bulletIndent1">The extended-release formulation of <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> is titrated according to the same schedule using the total daily dosage to determine the once-daily dosing. Adjustment for kidney impairment is required for both immediate- and extended-release formulations, and use of the extended-release formulation is not recommended in patients with severe kidney impairment (eg, creatinine clearance &lt;30 mL/minute).</p><p></p><p class="bulletIndent1">There is moderate-quality evidence supporting the efficacy of <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> for PHN, but some trials have failed to show a benefit with the extended-release formulation of gabapentin, and benefits beyond 12 weeks are uncertain [<a href="#rid43">43,48</a>]. In a meta-analysis including eight trials of more than 2200 patients with moderate to severe pain due to PHN, patients receiving gabapentin at a daily dose of 1200 mg or higher daily were more likely to report benefit (at least 50 percent reduction in pain intensity or "very much improved" pain) than those receiving placebo (32 versus 17 percent) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> is generally well tolerated. In a pooled analysis of adverse effects including 37 trials for multiple types of neuropathic pain, patients were more likely to discontinue gabapentin than placebo due to adverse effects (11 versus 8 percent) [<a href="#rid49">49</a>]. The most common adverse effects reported were somnolence or drowsiness (14 versus 5 percent), dizziness (19 versus 7 percent), peripheral edema (7 versus 2 percent), and ataxia or gait disturbance (14 versus 3 percent). The rate of serious adverse effects was 3 percent for both groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregabalin</strong> − The immediate-release formulation of <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> is given two or three times daily. Our titration regimen based on effect and tolerability is:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>75 mg twice daily for one week, then</p><p class="bulletIndent2"><span class="glyph">•</span>150 mg twice daily for one to three weeks, then</p><p class="bulletIndent2"><span class="glyph">•</span>300 mg twice daily</p><p></p><p class="bulletIndent1">An extended-release preparation is also available for once-daily dosing. The titration schedule is the same used for the immediate-release formulation; however, the starting dose is 165 mg daily and the maximum dose is 660 mg daily.</p><p></p><p class="bulletIndent1">When stopping the drug, <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> should be tapered over a week to reduce the risk of withdrawal symptoms [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1">Adjustment for kidney impairment is required for both the immediate- and extended-release formulations; the extended-release formulation is not recommended for patients with severe kidney impairment (eg, creatinine clearance &lt;30 mL/minute). <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> is designated as a schedule V controlled substance in the United States because it has been reported to cause euphoria.</p><p></p><p class="bulletIndent1">A systematic review of <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> for neuropathic pain identified eight trials including more than 2300 patients with PHN [<a href="#rid51">51</a>]. In the meta-analysis of 732 patients in four trials of patients with PHN, a dose response and significant reduction in pain (at least 50 percent) was more likely for patients receiving pregabalin than those receiving placebo: 150 mg (24 versus 13 percent), 300 mg (32 versus 13 percent), and 600 mg (41 versus 15 percent). Common side effects associated with pregabalin dosing included somnolence (300 mg, 16 percent; 600 mg, 25 percent) and dizziness (300 mg, 29 percent; 600 mg, 35 percent). Other side effects are dry mouth, peripheral edema, and weight gain.</p><p></p><p class="headingAnchor" id="H1749620941"><span class="h3">Tricyclic antidepressants if gabapentinoids ineffective or not tolerated</span><span class="headingEndMark"> — </span>For patients who do not tolerate or respond to a gabapentinoid, we suggest a TCA. They are frequently used for depression or other types of neuropathic pain and are also effective for PHN but have a lower tolerability than gabapentinoids [<a href="#rid52">52,53</a>]. For most patients using a TCA, we typically start with <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>; however, <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a> or <a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">desipramine</a> may be preferred for patients at risk for anticholinergic symptoms and those with adverse effects from amitriptyline.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">Amitriptyline</a> is started at 10 mg each night. The dose may be uptitrated as needed and tolerated over four weeks up to a dose of 50 mg each night. For patients who report minimal or no relief after one month at 50 mg, we switch to an alternative agent (see <a class="local">'Alternative therapies'</a> below). For those who report partial but inadequate relief at a dose of 50 mg, the dose may be further uptitrated every four weeks up to a maximum daily dose of 150 mg, monitoring for adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">Nortriptyline</a> is typically started at 10 mg each night and increased by 10 to 20 mg each week to effect as tolerated, with a maximum daily dose of 150 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">Desipramine</a> is typically started at 25 mg each night and increased by 25 mg each week to effect as tolerated, with a maximum daily dose of 150 mg.</p><p></p><p>TCAs inhibit the reuptake of norepinephrine and serotonin in the central nervous system. They are thought to increase the inhibition of nociceptive signals from the periphery [<a href="#rid54">54,55</a>].</p><p>Anticholinergic side effects (principally sedation and dry mouth) limit the tolerability of TCAs  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 1</a>) [<a href="#rid56">56</a>]. Because of their anticholinergic effects, TCAs should be used cautiously in older patients, particularly those with cognitive impairment or dementia. We also avoid TCAs in patients with heart disease, epilepsy, or glaucoma. Adverse effects may be reduced by using a slow titration; however, delayed onset of efficacy (up to three weeks) before TCAs begin to reduce pain may lead to premature discontinuation. A treatment trial of at least one month at a target dose may be needed to assess the efficacy of TCAs. In one study, symptom relief correlated with serum levels of <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> and active metabolites [<a href="#rid57">57</a>]. Patients who reported no benefit despite serum levels of 100 ng/mL for at least three weeks were considered to have failed TCA therapy.</p><p>A 2015 systematic review found moderate-quality evidence supporting the efficacy of TCAs for PHN [<a href="#rid43">43</a>]. Efficacy among TCAs is best established for <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, which was found effective in producing at least moderate pain relief in multiple short-term studies, typically at doses of 65 to 75 mg daily [<a href="#rid57">57,58</a>]. <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">Nortriptyline</a> was better tolerated than amitriptyline in a small crossover trial of 33 patients with PHN [<a href="#rid59">59</a>]. Approximately two-thirds of patients reported a good response with either medication, but adverse effects leading to discontinuation were more common with amitriptyline than nortriptyline (48 versus 30 percent). The small study size limits generalizability of these results. <a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">Desipramine</a> appears to have the fewest side effects of the first-generation TCAs and was effective for PHN in a small trial at mean dose 165 mg per day [<a href="#rid60">60,61</a>]. Almost half reported good response with desipramine. However, methodologic criticisms of this trial limit the certainty of these conclusions [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H799183186"><span class="h3">Topical therapy for patients with milder symptoms</span><span class="headingEndMark"> — </span>For patients with mild to moderate and localized pain and for those who prefer a topical agent, we suggest <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a>. We switch to <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> patches for those who do not tolerate capsaicin.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Capsaicin</strong> – <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">Capsaicin</a> is formulated as a cream, gel, lotion, or a high-concentration patch.</p><p></p><p class="bulletIndent1">We use <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> cream (0.025 to 0.075%) for most patients with PHN and reserve the high-concentration capsaicin (8%) patch for selected patients with partial response to capsaicin cream who prefer a longer acting formulation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">Capsaicin</a> cream may be applied to the affected area up to four times each day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-concentration <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> patches are administered as a single 60-minute application. The application may be repeated after three months. It must be administered by a health care professional, and patients are monitored for up to two hours after treatment. To manage local pain from capsaicin application, the skin is usually pretreated with a local anesthetic such as topical <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, and some studies also used post-treatment oral analgesics such as <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> for up to five days [<a href="#rid63">63</a>]. Further study is needed to confirm long-term effectiveness and tolerance of the high-concentration capsaicin patch.</p><p></p><p class="bulletIndent1">Limited data suggest that topical application of standard-concentration <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> is effective for PHN [<a href="#rid41">41</a>]. In one small trial, 143 patients with PHN assigned to capsaicin cream (0.075%) four times per day for six weeks were likelier to report significant pain relief than those assigned to placebo (21 versus 6 percent) [<a href="#rid64">64</a>]. The rate of adverse skin reactions was similar in patients receiving capsaicin and placebo.</p><p></p><p class="bulletIndent1">A 2013 systematic review identified four randomized controlled trials that evaluated 1272 subjects with PHN treated with one application of either high-concentration <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> patch or standard-concentration capsaicin. The only common endpoint reported by all four trials, a ≥30 percent pain intensity reduction at eight weeks compared with baseline, was significantly greater for high-concentration capsaicin patch (43 versus 34 percent; relative benefit 1.3, 95% CI 1.1-1.5) [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">High-concentration <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> patches are approved by the FDA for the treatment of PHN. However, capsaicin can cause burning, stinging, and erythema, making it difficult to achieve true blinding in clinical studies. In practice, application of capsaicin is intolerable in up to one-third of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lidocaine</strong> — <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">Lidocaine</a> patches (5%) may provide short term relief for PHN. Up to 3 patches may be applied over the affected area for up to 12 hours daily. </p><p></p><p class="bulletIndent1">Data from small trials and open-label studies suggest that topical <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> (5 percent) may be beneficial for pain relief in patients with PHN [<a href="#rid66">66</a>]. Lidocaine patches have been approved by the FDA for PHN. However, a 2014 systematic review of topical lidocaine for neuropathic pain (including 280 patients with PHN) found only very low quality evidence of efficacy of topical lidocaine due to small numbers, incomplete outcome assessments, and modest outcome measures of efficacy [<a href="#rid67">67</a>].</p><p></p><p class="headingAnchor" id="H526763659"><span class="h2">Alternative therapies</span><span class="headingEndMark"> — </span>For patients who do not tolerate or are unresponsive to initial therapy, we switch to an alternative agent  (<a class="graphic graphic_algorithm graphicRef133184" href="/d/graphic/133184.html" rel="external">algorithm 1</a>).<em> </em>For patients with a partial but suboptimal response with initial therapy, we use combination therapy by adding an alternative agent. We use patient preferences and medical comorbidities to help select among options.</p><p class="headingAnchor" id="H3445105497"><span class="h3">Antiseizure medications</span><span class="headingEndMark"> — </span>A trial of one of a (non-gabapentinoid) anticonvulsant agent may be useful for some patients who do not respond to or cannot tolerate initial medication options. Treatment decisions should be individualized based on patient characteristics, medical comorbidities, side effects, and drug interactions. The benefit of anticonvulsants is based in part on their efficacy in other neuropathic pain conditions such as trigeminal neuralgia and diabetic neuropathy and also on low-quality and anecdotal evidence for PHN. Options and typical target daily doses for PHN include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproic acid</a> 500 to 1000 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> 200 to 1200 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">Oxcarbazepine</a> 600 to 1200 mg daily</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> 100 to 300 mg daily</p><p></p><p>The dosing, titration, and monitoring of these agents for PHN is similar to regimens used in trigeminal neuralgia and typically lower doses than those to achieve anticonvulsant effects. (See  <a class="medical medical_review" href="/d/html/5283.html" rel="external">"Trigeminal neuralgia", section on 'Medical treatment'</a>.)</p><p>In an eight-week trial of 48 patients with PHN, patients assigned to divalproex sodium (1000 mg per day) were likelier to report at least moderate improvement in pain than those assigned to placebo (58 versus 15 percent) [<a href="#rid68">68</a>]. Results of small trials of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a> in other neuropathic pain conditions were mixed [<a href="#rid69">69</a>]. In short-term trials in patients with trigeminal neuralgia, both <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> reduced pain more than placebo, but neither drug was tested in patients with PHN [<a href="#rid70">70,71</a>]. <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> may be better tolerated than carbamazepine but has not been studied extensively for neuropathic pain.</p><p class="headingAnchor" id="H2159494693"><span class="h3">Serotonin-norepinephrine reuptake inhibitors</span><span class="headingEndMark"> — </span>Serotonin-norepinephrine reuptake inhibitors (SNRIs) may be useful for some patients with PHN based on efficacy data for painful polyneuropathy [<a href="#rid43">43</a>]. These medications may be useful for patients with comorbid depression. We use <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> or <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> for patients with PHN.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">Duloxetine</a> is typically started at 30 mg daily. Typical daily doses are 60 to 120 mg. The dose may be increased weekly to effect and as tolerated. Adverse effects including nausea, dry mouth, dizziness, and insomnia are more common at higher doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">Venlafaxine</a> may be started at 75 mg daily and increased every two weeks to effect as tolerated. Typical daily doses are 150 to 225 mg. Venlafaxine should be used with caution in patients with glaucoma and in those taking anticoagulants. Common adverse effects include nausea, dizziness, and somnolence.</p><p></p><p>The initial titration and administration of SNRIs are presented in greater detail separately. (See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p>The effectiveness of SNRIs such as <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> for patients with PHN is based on data for those with other types of neuropathic pain. A systematic review of eight trials and including 4084 patients found that duloxetine was beneficial for patients with painful diabetic neuropathy [<a href="#rid72">72</a>]. Venlafaxine was found to be effective in a short-term trial of 244 patients with painful diabetic polyneuropathy [<a href="#rid73">73</a>]. Patients assigned venlafaxine at 150 to 225 mg were likelier to report at least 50 percent pain reduction than those assigned placebo (50 versus 27 percent). However, a 2015 systematic review of six trials including 460 patients with neuropathic pain found only low-quality data of modest efficacy for venlafaxine [<a href="#rid74">74</a>]. The efficacy of SNRIs for diabetic neuropathy is presented in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5280.html" rel="external">"Management of diabetic neuropathy", section on 'Administration and efficacy'</a>.)</p><p class="headingAnchor" id="H1637839133"><span class="h2">Adjunctive options</span><span class="headingEndMark"> — </span>For patients with symptoms refractory to prior therapies, adjunctive options and other interventional therapies such as botulinum toxin injections may be tried or added  (<a class="graphic graphic_algorithm graphicRef133184" href="/d/graphic/133184.html" rel="external">algorithm 1</a>). These include oral or transdermal opioid analgesics and intrathecal glucocorticoid injections. The selection of these agents depends on individual patient preferences and comorbidities.</p><p class="headingAnchor" id="H10"><span class="h3">Opioids</span><span class="headingEndMark"> — </span>Opioids may be beneficial for selected patients with intractable pain during the titration of initial or alternative therapies. They can be administered simultaneously for short-term relief along with the nonopioid agents. They should be initiated at low doses if used and titrated to provide relief while awaiting benefit from nonopioid treatments, at which point opioids should be tapered off.</p><p>Opioids are available in short- or long-acting formulations  (<a class="graphic graphic_table graphicRef108947" href="/d/graphic/108947.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef108954" href="/d/graphic/108954.html" rel="external">table 3</a>). We start with short-acting options for opioid-naïve patients and use the lowest effective dose. The strategies for initiation and chronic use of opioids for patients with PHN is similar to that of other patients with noncancer pain and is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain"</a>.)</p><p>Small trials support the efficacy of opioid analgesics for PHN [<a href="#rid75">75-79</a>]. In one crossover trial involving 76 patients with PHN, treatment with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> (mean daily dose 91 mg) or <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> (mean daily dose 15 mg) or a TCA for eight weeks was more effective than placebo [<a href="#rid77">77</a>]. There was a trend toward greater pain relief with opioids, but certainty with these results is limited by small sample size.</p><p>The use of opioids for chronic PHN should be avoided. Opioids for chronic noncancer pain remains controversial due to the risk of physical dependence, tolerance, addiction, and overdose. Because of these risks, opioids are regarded as third-line treatment options and typically reserved for short-term, adjunctive use for PHN [<a href="#rid38">38,43,80</a>]. Available trials of opioids for neuropathic pain including PHN do not address the issues of abuse and addiction [<a href="#rid81">81</a>]. Pharmacovigilance is essential to using opioids in any population  (<a class="graphic graphic_table graphicRef50477" href="/d/graphic/50477.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Neuraxial glucocorticoid infusion</span><span class="headingEndMark"> — </span>Intrathecal glucocorticoid injections may be beneficial for patients who continue to have intractable pain despite initial or alternative therapies. These injections are not useful for pain in the distribution of the trigeminal nerve.</p><p>Intrathecal glucocorticoids for PHN are typically given as a single course of weekly injections over four weeks [<a href="#rid82">82</a>]. Techniques for intrathecal glucocorticoid infusion are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/105456.html" rel="external">"Spinal anesthesia: Technique"</a>.)</p><p>Intrathecal glucocorticoid injections are associated with an uncertain but probably low risk of serious adverse events, including aseptic meningitis, transverse myelitis, cauda equina syndrome, lumbar radiculitis, headache, urinary retention, and arachnoiditis [<a href="#rid83">83,84</a>].</p><p>Some [<a href="#rid40">40,82,85</a>] but not all [<a href="#rid86">86</a>] studies have found a benefit with intrathecal <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> infusions for patients with PHN. The largest trial evaluated 277 patients with intractable PHN who were assigned to one of three treatment groups: intrathecal methylprednisolone plus <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> once per week for four weeks, intrathecal lidocaine alone once per week for four weeks, or no treatment [<a href="#rid82">82</a>]. More than 90 percent of patients in the methylprednisolone group reported excellent or good pain relief both at four weeks compared with 6 and 4 percent in the lidocaine and no treatment groups, respectively. These results were sustained at two-year follow-up. There were no serious adverse events associated with the injection.</p><p>Intrathecal administration of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> was found more effective than administration in the epidural space in a small trial of 25 patients with PHN [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H1907947860"><span class="h2">Therapies for refractory symptoms</span><span class="headingEndMark"> — </span>We reserve other interventional and surgical approaches such as botulinum toxin injections, cryotherapy, and neuromodulation for patients with refractory symptoms who do not respond to other therapies  (<a class="graphic graphic_algorithm graphicRef133184" href="/d/graphic/133184.html" rel="external">algorithm 1</a>). The benefit of such therapies has been shown in small trials and observational studies; larger studies are needed to better define their role for patients with PHN.</p><p class="headingAnchor" id="H799183120"><span class="h3">Botulinum toxin</span><span class="headingEndMark"> — </span>Botulinum toxin injection for PHN is not extensively studied, but evidence from observational studies and small trials suggests it is effective [<a href="#rid87">87-90</a>]. One trial evaluated 30 adults with PHN who had persistent pain for at least three months [<a href="#rid87">87</a>]. Patients assigned to botulinum toxin type A (<a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a>) injections were likelier to achieve ≥50 percent pain reduction at two weeks compared with those who received placebo injections (13 of 15 patients [87 percent] versus none of 15). The benefit persisted for a median of 16 weeks. In a comparative study of 60 patients with PHN, patients who received onabotulinumtoxinA injection reported a greater pain reduction at seven days when rated on the visual analog scale compared with those who received <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> injections (4.5 versus 2.6 points) [<a href="#rid88">88</a>]. These findings were sustained at three months. Improvement in sleep and reduction in opiate use were also reported in the botulinum toxin group.</p><p>Botulinum toxin injections should be performed by a clinician experienced with this treatment [<a href="#rid91">91-93</a>]. No safety concerns were identified in small studies [<a href="#rid87">87,88</a>]. However, botulinum toxin may cause localized or systemic adverse effects including bruising, weakness, pain, or headache and may be contraindicated for some patients. Larger and longer-term studies would be helpful to further clarify the safety and efficacy on this treatment in PHN.</p><p class="headingAnchor" id="H1040167579"><span class="h3">Neuromodulation and nerve stimulation</span><span class="headingEndMark"> — </span>Invasive neuromodulatory strategies such as spinal cord stimulation and peripheral nerve stimulation are considered experimental. These techniques target peripheral nerves and are thought to modulate neuronal signaling or inflammatory processes [<a href="#rid94">94</a>]. Techniques that have shown some benefit for patients with PHN include:</p><p class="bulletIndent1"><span class="glyph">●</span>Transcutaneous electrical nerve stimulation (TENS) [<a href="#rid95">95</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Pulsed radiofrequency [<a href="#rid96">96-100</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal cord stimulation [<a href="#rid101">101,102</a>]</p><p></p><p>These techniques been reported to be effective in approximately half of patients in case reports and case series [<a href="#rid103">103</a>]. They should be performed by experienced clinicians and in centers with expertise.</p><p class="headingAnchor" id="H1307981873"><span class="h3">Cognitive and behavioral therapies</span><span class="headingEndMark"> — </span>Some patients with PHN achieve only partial relief even with combination pharmacotherapy. For other patients, the efficacy of pharmacotherapy is limited by adverse effects. Nonpharmacologic approaches, including cognitive-behavioral therapy (CBT), may be useful for some patients with refractory PHN pain or associated impairment in mood, sleep, or other quality-of-life domains [<a href="#rid104">104,105</a>]. In a small trial of 40 patients with PHN treated with <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>, patients who were assigned to also receive CBT reported a greater improvement in pain intensity and mood symptoms than those assigned to pregabalin alone [<a href="#rid106">106</a>]. Cognitive and behavioral therapies for the treatment of chronic pain are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults", section on 'Psychological therapy'</a>.)</p><p class="headingAnchor" id="H1222869173"><span class="h3">Therapies of uncertain or limited benefit</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NMDA receptor antagonists</strong> – Animal data suggest a role for excitatory amino acid neurotransmitters in the maintenance of chronic pain due to nerve injury [<a href="#rid107">107,108</a>]. Antagonists of the N-methyl-D-aspartate (NMDA) receptor have been shown to relieve neuropathic pain in humans [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1">The most widely available NMDA receptor antagonists are <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> and <a class="drug drug_general" data-topicid="8893" href="/d/drug information/8893.html" rel="external">dextromethorphan</a>. Intravenous ketamine induces modest pain relief in patients with PHN but at doses that cause sedation, dysphoria, and dissociative episodes [<a href="#rid110">110</a>]. In a crossover trial, pain relief after six weeks was similar in those taking dextromethorphan or placebo [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><strong>lidocaine</strong> – Small trials have failed to find sustained benefit of intravenous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> compared with placebo in patients with PHN [<a href="#rid40">40,112</a>]. Any temporary changes in pain measured immediately after infusion do not appear to be sustained by four weeks [<a href="#rid40">40,112-116</a>].</p><p></p><p class="bulletIndent1">The role of topical <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> for PHN is discussed separately. (See <a class="local">'Topical therapy for patients with milder symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical ablation and other interventional procedures</strong> – Cryotherapy is an ablation technique that involves freezing peripheral nerves. A small, unblinded study of cryotherapy for facial pain failed to show a significant benefit in patients with PHN [<a href="#rid117">117</a>]. The authors did not provide inclusion criteria, concomitant therapies, or information on how the response was assessed. By contrast, a second trial reported "considerable" relief in 11 of 14 patients with cryotherapy to the intercostal nerves for PHN [<a href="#rid118">118</a>]. In most cases, however, the duration of relief was less than two weeks as assessed by questionnaire.</p><p></p><p class="bulletIndent1">Surgical interventions including central electrical stimulation of the thalamus, ablation by anterolateral cordotomy, and electrocoagulation of the dorsal root carry substantial risks of permanent neurologic deficits. A systematic review of surgical procedures for patients with refractory PHN reported the pain reduction with surgical ablation procedures was frequently accompanied by serious complications including neuromuscular weakness [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Simple analgesics</strong> – Analgesic medications such as <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or other nonsteroidal anti-inflammatory drugs are of limited value in patients with either acute herpetic neuralgia or PHN [<a href="#rid38">38,120</a>].</p><p></p><p class="headingAnchor" id="H336152680"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The pain of PHN may persist for months, years, or even life [<a href="#rid38">38</a>]. However, there are few published data for follow-up beyond one year. Prognostic data on PHN is available from long-term outcome of observational studies in acute herpes zoster. In one study of 85 patients with PHN who were followed to one year, moderate to severe neuropathic pain persisted in approximately 55 percent [<a href="#rid121">121</a>]. In a long-term follow-up of a study that included 158 of 298 original patients from an acute herpes zoster trial, 21 percent of patients reported long-term pain (mean follow-up 9 years) [<a href="#rid122">122</a>].</p><p>In a questionnaire study of 385 adults age ≥65 years with persistent PHN, the mean duration of symptoms was 3.3 years [<a href="#rid123">123</a>].</p><p class="headingAnchor" id="H336152712"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention of PHN involves either treatment of acute zoster or the use of a vaccine to decrease the incidence of acute zoster and PHN. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a> and  <a class="medical medical_review" href="/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals"</a>.)</p><p class="headingAnchor" id="H1566456967"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110219.html" rel="external">"Society guideline links: Varicella-zoster virus"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115871.html" rel="external">"Society guideline links: Neuropathic pain"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/82819.html" rel="external">"Patient education: Neuropathic pain (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4023.html" rel="external">"Patient education: Shingles (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and risk factors</strong> – Postherpetic neuralgia (PHN) refers to pain persisting beyond three months from the initial onset of the rash associated with a prior acute herpes zoster episode. The major risk factors for PHN are age &gt;60 years and severe pain and rash with a preceding acute herpes zoster episode. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – PHN is most often a continuation of pain that failed to resolve following an acute episode of herpes zoster but may develop months to years after resolution of the initial acute event. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">The pain is localized to a dermatome. Thoracic (especially T4 to T6), cervical, and trigeminal nerves are most commonly affected with PHN. The neuropathic pain associated with PHN can be burning, pruritic, sharp, or stabbing and constant or intermittent. Many patients also report allodynia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of PHN is made when localized neuropathic pain persists beyond three months in the same distribution as a preceding documented episode of acute herpes zoster. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments</strong> – PHN can be difficult to treat and some patients require multimodal therapy for symptomatic management. The choice among treatments for PHN should be individualized according to severity and location of pain, comorbid conditions, medication side effect profile, treatment cost and availability, and patient values and preferences  (<a class="graphic graphic_algorithm graphicRef133184" href="/d/graphic/133184.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapies</strong> – For most patients, we suggest a gabapentinoid (<a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>) as initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Tricyclic antidepressant medications are a reasonable alternative to gabapentinoids. Topical treatments (eg, <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a>) are another reasonable alternative for patients with milder symptoms and for those who prefer a topical therapy. (See <a class="local">'Gabapentinoids for most patients with moderate or severe pain'</a> above and <a class="local">'Tricyclic antidepressants if gabapentinoids ineffective or not tolerated'</a> above and <a class="local">'Topical therapy for patients with milder symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative therapies</strong> – For patients who do not tolerate or are unresponsive to initial therapies, we add or switch to an alternative agent. Medications with evidence of efficacy for PHN or other types of neuropathic pain include other antiseizure medications (eg, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>) and serotonin-norepinephrine reuptake inhibitors (eg, <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>). (See <a class="local">'Alternative therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjunctive options and therapies for refractory symptoms</strong> – For patients with partial response to initial or alternative therapies, adjunctive options may provide additional benefit. These include oral or transdermal opioid analgesics and intrathecal glucocorticoid injections. We reserve other interventional and surgical approaches such as botulinum toxin injections, cryotherapy, and neuromodulation for patients with refractory symptoms who do not respond to other therapies. (See <a class="local">'Adjunctive options'</a> above and <a class="local">'Therapies for refractory symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The pain of PHN may persist for months, years, or even life. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H4104662620"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Zahid H Bajwa, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Watson CP, Morshead C, Van der Kooy D, et al. Post-herpetic neuralgia: post-mortem analysis of a case. Pain 1988; 34:129.</a></li><li><a class="nounderline abstract_t">Woolf CJ. Recent advances in the pathophysiology of acute pain. Br J Anaesth 1989; 63:139.</a></li><li><a class="nounderline abstract_t">LaMotte RH, Shain CN, Simone DA, Tsai EF. Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol 1991; 66:190.</a></li><li><a class="nounderline abstract_t">Simone DA, Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 1989; 38:99.</a></li><li><a class="nounderline abstract_t">Cline MA, Ochoa J, Torebjörk HE. Chronic hyperalgesia and skin warming caused by sensitized C nociceptors. Brain 1989; 112 ( Pt 3):621.</a></li><li><a class="nounderline abstract_t">Bennett GJ. Hypotheses on the pathogenesis of herpes zoster-associated pain. Ann Neurol 1994; 35 Suppl:S38.</a></li><li><a class="nounderline abstract_t">Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers 2015; 1:15016.</a></li><li><a class="nounderline abstract_t">Burke BL, Steele RW, Beard OW, et al. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142:291.</a></li><li><a class="nounderline abstract_t">Meier JL, Straus SE. Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J Infect Dis 1992; 166 Suppl 1:S13.</a></li><li><a class="nounderline abstract_t">Fitzgerald PJ, Denny-Brown D, Adams RD. Pathologic features of herpes zoster: A note on 'geniculate herpes'. Arch Neurol Psychiatr 1944; 51:216.</a></li><li><a class="nounderline abstract_t">Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900; 23:353.</a></li><li><a class="nounderline abstract_t">ZACKS SI, ELLIOTT FA, LANGFITT TW. HERPETIC NEURITIS: A LIGHT AND ELECTRON MICROSCOPIC STUDY. Neurology 1964; 14:744.</a></li><li><a class="nounderline abstract_t">Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67:241.</a></li><li><a class="nounderline abstract_t">Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9:S37.</a></li><li><a class="nounderline abstract_t">Arani RB, Soong SJ, Weiss HL, et al. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med 2001; 20:2429.</a></li><li><a class="nounderline abstract_t">Watson CP, Deck JH, Morshead C, et al. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991; 44:105.</a></li><li><a class="nounderline abstract_t">Üçeyler N, Valet M, Kafke W, et al. Local and systemic cytokine expression in patients with postherpetic neuralgia. PLoS One 2014; 9:e105269.</a></li><li><a class="nounderline abstract_t">Cao S, Zhang D, Yuan J, et al. Inflammatory cytokine expression in the skin of patients with postherpetic neuralgia. J Int Med Res 2020; 48:300060520929582.</a></li><li><a class="nounderline abstract_t">Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342:635.</a></li><li><a class="nounderline abstract_t">Acosta EP, Balfour HH Jr. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Chemother 2001; 45:2771.</a></li><li><a class="nounderline abstract_t">Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.</a></li><li><a class="nounderline abstract_t">Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321:794.</a></li><li><a class="nounderline abstract_t">Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl 1:S76.</a></li><li><a class="nounderline abstract_t">Nagasako EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol 2002; 46:834.</a></li><li><a class="nounderline abstract_t">Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis 1999; 179:9.</a></li><li><a class="nounderline abstract_t">Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62:1545.</a></li><li><a class="nounderline abstract_t">Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study. Neurology 2016; 87:94.</a></li><li><a class="nounderline abstract_t">Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61:310.</a></li><li><a class="nounderline abstract_t">Balfour HH Jr. Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am J Med 1988; 85:68.</a></li><li><a class="nounderline abstract_t">Drolet M, Brisson M, Schmader K, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010; 11:1211.</a></li><li><a class="nounderline abstract_t">Schott GD. Triggering of delayed-onset postherpetic neuralgia. Lancet 1998; 351:419.</a></li><li><a class="nounderline abstract_t">Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8:37.</a></li><li><a class="nounderline abstract_t">Bowsher D. Pathophysiology of postherpetic neuralgia: towards a rational treatment. Neurology 1995; 45:S56.</a></li><li><a class="nounderline abstract_t">Watson CP, Evans RJ, Watt VR, Birkett N. Post-herpetic neuralgia: 208 cases. Pain 1988; 35:289.</a></li><li><a class="nounderline abstract_t">Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010; 182:1731.</a></li><li><a class="nounderline abstract_t">Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging 2012; 29:863.</a></li><li><a class="nounderline abstract_t">Gilden DH, Wright RR, Schneck SA, et al. Zoster sine herpete, a clinical variant. Ann Neurol 1994; 35:530.</a></li><li><a class="nounderline abstract_t">Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014; 371:1526.</a></li><li><a class="nounderline abstract_t">Liu X, Wei L, Zeng Q, et al. The Treatment of Topical Drugs for Postherpetic Neuralgia: A Network Meta-Analysis. Pain Physician 2020; 23:541.</a></li><li><a class="nounderline abstract_t">Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2:e164.</a></li><li><a class="nounderline abstract_t">Edelsberg JS, Lord C, Oster G. Systematic review and meta-analysis of efficacy, safety, and tolerability data from randomized controlled trials of drugs used to treat postherpetic neuralgia. Ann Pharmacother 2011; 45:1483.</a></li><li><a class="nounderline abstract_t">Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113.</a></li><li><a class="nounderline abstract_t">Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14:162.</a></li><li><a class="nounderline abstract_t">Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 63:959.</a></li><li><a class="nounderline abstract_t">Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; :CD007938.</a></li><li><a class="nounderline abstract_t">Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995; 18:469.</a></li><li><a class="nounderline abstract_t">Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl 6:13.</a></li><li><a class="nounderline abstract_t">Moore A, Derry S, Wiffen P. Gabapentin for Chronic Neuropathic Pain. JAMA 2018; 319:818.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6:CD007938.</a></li><li><a class="nounderline abstract_t">Pregabalin (lyrica) for neuropathic pain and epilepsy. Med Lett Drugs Ther 2005; 47:75.</a></li><li><a class="nounderline abstract_t">Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019; 1:CD007076.</a></li><li><a class="nounderline abstract_t">Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med 2011; 123:134.</a></li><li><a class="nounderline abstract_t">Chandra K, Shafiq N, Pandhi P, et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. Int J Clin Pharmacol Ther 2006; 44:358.</a></li><li><a class="nounderline abstract_t">Dubner R, Bennett GJ. Spinal and trigeminal mechanisms of nociception. Annu Rev Neurosci 1983; 6:381.</a></li><li><a class="nounderline abstract_t">Basbaum AI, Fields HL. Endogenous pain control mechanisms: review and hypothesis. Ann Neurol 1978; 4:451.</a></li><li><a class="nounderline abstract_t">By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2015; 63:2227.</a></li><li><a class="nounderline abstract_t">Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38:1427.</a></li><li><a class="nounderline abstract_t">Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32:671.</a></li><li><a class="nounderline abstract_t">Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51:1166.</a></li><li><a class="nounderline abstract_t">DasGupta K. Treatment of depression in elderly patients: recent advances. Arch Fam Med 1998; 7:274.</a></li><li><a class="nounderline abstract_t">Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990; 47:305.</a></li><li><a class="nounderline abstract_t">Hearn L, Moore RA, Derry S, et al. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev 2014; :CD011003.</a></li><li><a class="nounderline abstract_t">Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008; 7:1106.</a></li><li><a class="nounderline abstract_t">Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993; 15:510.</a></li><li><a class="nounderline abstract_t">Derry S, Rice AS, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 1:CD007393.</a></li><li><a class="nounderline abstract_t">Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand 2011; 123:295.</a></li><li><a class="nounderline abstract_t">Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 2014; :CD010958.</a></li><li><a class="nounderline abstract_t">Kochar DK, Garg P, Bumb RA, et al. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. QJM 2005; 98:29.</a></li><li><a class="nounderline abstract_t">Aiyer R, Mehta N, Gungor S, Gulati A. A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice. Clin J Pain 2018; 34:450.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; :CD005451.</a></li><li><a class="nounderline abstract_t">Bennetto L, Patel NK, Fuller G. Trigeminal neuralgia and its management. BMJ 2007; 334:201.</a></li><li><a class="nounderline abstract_t">Hossain SM, Hussain SM, Ekram AR. Duloxetine in Painful Diabetic Neuropathy: A Systematic Review. Clin J Pain 2016; 32:1005.</a></li><li><a class="nounderline abstract_t">Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110:697.</a></li><li><a class="nounderline abstract_t">Gallagher HC, Gallagher RM, Butler M, et al. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev 2015; :CD011091.</a></li><li><a class="nounderline abstract_t">Max MB, Schafer SC, Culnane M, et al. Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 1988; 43:363.</a></li><li><a class="nounderline abstract_t">Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41:1024.</a></li><li><a class="nounderline abstract_t">Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59:1015.</a></li><li><a class="nounderline abstract_t">Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003; 104:323.</a></li><li><a class="nounderline abstract_t">Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50:1837.</a></li><li><a class="nounderline abstract_t">Harden RN, Kaye AD, Kintanar T, Argoff CE. Evidence-based guidance for the management of postherpetic neuralgia in primary care. Postgrad Med 2013; 125:191.</a></li><li><a class="nounderline abstract_t">McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev 2013; :CD006146.</a></li><li><a class="nounderline abstract_t">Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343:1514.</a></li><li><a class="nounderline abstract_t">Nelson DA. Intraspinal therapy using methylprednisolone acetate. Twenty-three years of clinical controversy. Spine (Phila Pa 1976) 1993; 18:278.</a></li><li><a class="nounderline abstract_t">Nelson DA, Landau WM. Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports. J Neurol Neurosurg Psychiatry 2001; 70:433.</a></li><li><a class="nounderline abstract_t">Kikuchi A, Kotani N, Sato T, et al. Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia. Reg Anesth Pain Med 1999; 24:287.</a></li><li><a class="nounderline abstract_t">Rijsdijk M, van Wijck AJ, Meulenhoff PC, et al. No beneficial effect of intrathecal methylprednisolone acetate in postherpetic neuralgia patients. Eur J Pain 2013; 17:714.</a></li><li><a class="nounderline abstract_t">Apalla Z, Sotiriou E, Lallas A, et al. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain 2013; 29:857.</a></li><li><a class="nounderline abstract_t">Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010; 11:1827.</a></li><li><a class="nounderline abstract_t">Hu Y, Zou L, Qi X, et al. Subcutaneous botulinum toxin-A injection for treating postherpetic neuralgia. Dermatol Ther 2020; 33:e13181.</a></li><li><a class="nounderline abstract_t">Jain P, Jain M, Jain S. Subcutaneous Injection of Botulinum Toxin in Patients with Post Herpetic Neuralgia. A Preliminary Study. J Assoc Physicians India 2018; 66:48.</a></li><li><a class="nounderline abstract_t">Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 2003; 29:549.</a></li><li><a class="nounderline abstract_t">Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004; 20:981.</a></li><li><a class="nounderline abstract_t">Rodrigues FB, Duarte GS, Marques RE, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2020; 11:CD003633.</a></li><li><a class="nounderline abstract_t">Lin CS, Lin YC, Lao HC, Chen CC. Interventional Treatments for Postherpetic Neuralgia: A Systematic Review. Pain Physician 2019; 22:209.</a></li><li><a class="nounderline abstract_t">Borghi A, Rimessi A, Minghetti S, et al. Efficacy of magnesium chloride in the treatment of Hailey-Hailey disease: from serendipity to evidence of its effect on intracellular Ca(2+) homeostasis. Int J Dermatol 2015; 54:543.</a></li><li><a class="nounderline abstract_t">Ke M, Yinghui F, Yi J, et al. Efficacy of pulsed radiofrequency in the treatment of thoracic postherpetic neuralgia from the angulus costae: a randomized, double-blinded, controlled trial. Pain Physician 2013; 16:15.</a></li><li><a class="nounderline abstract_t">Saxena AK, Lakshman K, Sharma T, et al. Modulation of serum BDNF levels in postherpetic neuralgia following pulsed radiofrequency of intercostal nerve and pregabalin. Pain Manag 2016; 6:217.</a></li><li><a class="nounderline abstract_t">Pi ZB, Lin H, He GD, et al. Randomized and controlled prospective trials of Ultrasound-guided spinal nerve posterior ramus pulsed radiofrequency treatment for lower back post-herpetic neuralgia. Clin Ter 2015; 166:e301.</a></li><li><a class="nounderline abstract_t">Makharita MY, El Bendary HM, Sonbul ZM, et al. Ultrasound-guided Pulsed Radiofrequency in the Management of Thoracic Postherpetic Neuralgia: A Randomized, Double-blinded, Controlled Trial. Clin J Pain 2018; 34:1017.</a></li><li><a class="nounderline abstract_t">Ding Y, Li H, Hong T, Yao P. Efficacy of Pulsed Radiofrequency to Cervical Nerve Root for Postherpetic Neuralgia in Upper Extremity. Front Neurosci 2020; 14:377.</a></li><li><a class="nounderline abstract_t">Yanamoto F, Murakawa K. The effects of temporary spinal cord stimulation (or spinal nerve root stimulation) on the management of early postherpetic neuralgia from one to six months of its onset. Neuromodulation 2012; 15:151.</a></li><li><a class="nounderline abstract_t">Naja ZM, Maaliki H, Al-Tannir MA, et al. Repetitive paravertebral nerve block using a catheter technique for pain relief in post-herpetic neuralgia. Br J Anaesth 2006; 96:381.</a></li><li><a class="nounderline abstract_t">Kurklinsky S, Palmer SC, Arroliga MJ, Ghazi SM. Neuromodulation in Postherpetic Neuralgia: Case Reports and Review of the Literature. Pain Med 2018; 19:1237.</a></li><li><a class="nounderline abstract_t">Zhu X, Hu P, Fan Z, et al. Effects of Mindfulness-Based Stress Reduction on Depression, Anxiety, and Pain in Patients With Postherpetic Neuralgia. J Nerv Ment Dis 2019; 207:482.</a></li><li><a class="nounderline abstract_t">Meize-Grochowski R, Shuster G, Boursaw B, et al. Mindfulness meditation in older adults with postherpetic neuralgia: a randomized controlled pilot study. Geriatr Nurs 2015; 36:154.</a></li><li><a class="nounderline abstract_t">Saxena AK, Bhardwaj N, Chilkoti GT, et al. Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study. Pain Med 2021; 22:2276.</a></li><li><a class="nounderline abstract_t">Wu LJ, Zhuo M. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics 2009; 6:693.</a></li><li><a class="nounderline abstract_t">Chizh BA, Headley PM. NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. Curr Pharm Des 2005; 11:2977.</a></li><li><a class="nounderline abstract_t">Kristensen JD, Svensson B, Gordh T Jr. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 1992; 51:249.</a></li><li><a class="nounderline abstract_t">Eide PK, Jørum E, Stubhaug A, et al. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 1994; 58:347.</a></li><li><a class="nounderline abstract_t">Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48:1212.</a></li><li><a class="nounderline abstract_t">Moulin DE, Morley-Forster PK, Pirani Z, et al. Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial. Can J Anaesth 2019; 66:820.</a></li><li><a class="nounderline abstract_t">Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage 1999; 17:429.</a></li><li><a class="nounderline abstract_t">Kim YC, Castañeda AM, Lee CS, et al. Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study. Reg Anesth Pain Med 2018; 43:415.</a></li><li><a class="nounderline abstract_t">Liu H, Lu F, Zhou D, et al. The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study. Clin J Pain 2018; 34:1025.</a></li><li><a class="nounderline abstract_t">Tan X, Ma L, Yuan J, et al. Intravenous infusion of lidocaine enhances the efficacy of conventional treatment of postherpetic neuralgia. J Pain Res 2019; 12:2537.</a></li><li><a class="nounderline abstract_t">Barnard D, Lloyd J, Evans J. Cryoanalgesia in the management of chronic facial pain. J Maxillofac Surg 1981; 9:101.</a></li><li><a class="nounderline abstract_t">Jones MJ, Murrin KR. Intercostal block with cryotherapy. Ann R Coll Surg Engl 1987; 69:261.</a></li><li><a class="nounderline abstract_t">Texakalidis P, Tora MS, Boulis NM. Neurosurgeons' Armamentarium for the Management of Refractory Postherpetic Neuralgia: A Systematic Literature Review. Stereotact Funct Neurosurg 2019; 97:55.</a></li><li><a class="nounderline abstract_t">Vo T, Rice AS, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain 2009; 143:169.</a></li><li><a class="nounderline abstract_t">Pica F, Gatti A, Divizia M, et al. One-year follow-up of patients with long-lasting post-herpetic neuralgia. BMC Infect Dis 2014; 14:556.</a></li><li><a class="nounderline abstract_t">McKendrick MW, Ogan P, Care CC. A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster. J Infect 2009; 59:416.</a></li><li><a class="nounderline abstract_t">Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6:356.</a></li></ol></div><div id="topicVersionRevision">Topic 5289 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3174152" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Post-herpetic neuralgia: post-mortem analysis of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2669905" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recent advances in the pathophysiology of acute pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1919666" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2780068" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2731024" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic hyperalgesia and skin warming caused by sensitized C nociceptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8185295" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypotheses on the pathogenesis of herpes zoster-associated pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27188665" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Varicella zoster virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6277260" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immune responses to varicella-zoster in the aged.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320646" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparative biology of latent varicella-zoster virus and herpes simplex virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pathologic features of herpes zoster: A note on 'geniculate herpes'</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The pathology of herpes zoster and its bearing on sensory localization</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14206565" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : HERPETIC NEURITIS: A LIGHT AND ELECTRON MICROSCOPIC STUDY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951917" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pain and its persistence in herpes zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166464" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11512133" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phase specific analysis of herpes zoster associated pain data: a new statistical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1711192" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Post-herpetic neuralgia: further post-mortem studies of cases with and without pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25127283" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Local and systemic cytokine expression in patients with postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32840164" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Inflammatory cytokine expression in the skin of patients with postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699164" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neurologic complications of the reactivation of varicella-zoster virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11557467" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930418" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11009518" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852980" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063479" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841816" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Herpes zoster: risk categories for persistent pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136679" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors for postherpetic neuralgia in patients with herpes zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27287218" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6981045" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Population-based study of herpes zoster and its sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3044096" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20434957" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482304" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Triggering of delayed-onset postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20565946" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8545023" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pathophysiology of postherpetic neuralgia: towards a rational treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2852344" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Post-herpetic neuralgia: 208 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921251" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23038608" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnosing and managing postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179298" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Zoster sine herpete, a clinical variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25317872" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical practice. Postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33185370" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Treatment of Topical Drugs for Postherpetic Neuralgia: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16013891" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22085778" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Systematic review and meta-analysis of efficacy, safety, and tolerability data from randomized controlled trials of drugs used to treat postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20402746" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575710" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452284" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412914" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gabapentin for chronic neuropathic pain and fibromyalgia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8681309" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gabapentin: pharmacokinetics, efficacy, and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15315511" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pregabalin pharmacology and its relevance to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29486015" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Gabapentin for Chronic Neuropathic Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28597471" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gabapentin for chronic neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151369" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pregabalin (lyrica) for neuropathic pain and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30673120" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pregabalin for neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21904096" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Review of current guidelines on the care of postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961166" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6132587" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Spinal and trigeminal mechanisms of nociception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/216303" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endogenous pain control mechanisms: review and hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26446832" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3412591" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Amitriptyline, but not lorazepam, relieves postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6283422" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Amitriptyline versus placebo in postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781549" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596464" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of depression in elderly patients: recent advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178851" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Desipramine relieves postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246131" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Desipramine for neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977178" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8364943" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28085183" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Topical capsaicin (high concentration) for chronic neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039364" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25058164" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Topical lidocaine for neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625351" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28877137" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719027" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Carbamazepine for chronic neuropathic pain and fibromyalgia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255614" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Trigeminal neuralgia and its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26710221" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Duloxetine in Painful Diabetic Neuropathy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288411" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26298465" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Venlafaxine for neuropathic pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281774" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1712433" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370455" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12855342" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633737" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23933906" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evidence-based guidance for the management of postherpetic neuralgia in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23986501" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Opioids for neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087880" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intrathecal methylprednisolone for intractable postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441945" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Intraspinal therapy using methylprednisolone acetate. Twenty-three years of clinical controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254764" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10445766" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23059790" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : No beneficial effect of intrathecal methylprednisolone acetate in postherpetic neuralgia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370074" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134121" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31769900" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Subcutaneous botulinum toxin-A injection for treating postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31325262" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Subcutaneous Injection of Botulinum Toxin in Patients with Post Herpetic Neuralgia. A Preliminary Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752527" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Complications, adverse reactions, and insights with the use of botulinum toxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265242" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Safety of botulinum toxin type A: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33180963" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Botulinum toxin type A therapy for cervical dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31151330" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Interventional Treatments for Postherpetic Neuralgia: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25430969" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy of magnesium chloride in the treatment of Hailey-Hailey disease: from serendipity to evidence of its effect on intracellular Ca(2+) homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23340530" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Efficacy of pulsed radiofrequency in the treatment of thoracic postherpetic neuralgia from the angulus costae: a randomized, double-blinded, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27094801" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Modulation of serum BDNF levels in postherpetic neuralgia following pulsed radiofrequency of intercostal nerve and pregabalin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26550813" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Randomized and controlled prospective trials of Ultrasound-guided spinal nerve posterior ramus pulsed radiofrequency treatment for lower back post-herpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29757758" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ultrasound-guided Pulsed Radiofrequency in the Management of Thoracic Postherpetic Neuralgia: A Randomized, Double-blinded, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32372914" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Efficacy of Pulsed Radiofrequency to Cervical Nerve Root for Postherpetic Neuralgia in Upper Extremity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22376181" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The effects of temporary spinal cord stimulation (or spinal nerve root stimulation) on the management of early postherpetic neuralgia from one to six months of its onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16431881" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Repetitive paravertebral nerve block using a catheter technique for pain relief in post-herpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29016994" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Neuromodulation in Postherpetic Neuralgia: Case Reports and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31045954" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effects of Mindfulness-Based Stress Reduction on Depression, Anxiety, and Pain in Patients With Postherpetic Neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784079" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Mindfulness meditation in older adults with postherpetic neuralgia: a randomized controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34097069" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789073" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16178757" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1484720" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7838584" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153445" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31098961" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388248" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381569" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29698250" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31686896" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Intravenous infusion of lidocaine enhances the efficacy of conventional treatment of postherpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6167650" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cryoanalgesia in the management of chronic facial pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2447819" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intercostal block with cryotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30995653" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Neurosurgeons' Armamentarium for the Management of Refractory Postherpetic Neuralgia: A Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362418" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361823" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : One-year follow-up of patients with long-lasting post-herpetic neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766139" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15943957" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
